Cholesterol drug for slowing aortic valve disease
Part of Heart & circulation clinical trials.
This trial tests whether a newer cholesterol-lowering medicine can slow down the narrowing of the heart's main valve in people with aortic stenosis. If you qualify, you may be able to take this medicine to potentially delay the need for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have aortic stenosis (a narrowing of the heart's main valve) confirmed by an echocardiogram.
- You also have heart or blood vessel disease, or very high LDL-C (bad cholesterol) levels.
- You have taken the highest dose of a statin that you can tolerate, but your cholesterol is still not at target.
- You have not used PCSK9 inhibitor medicines before and are not allergic to them.
- You are not planning to have valve replacement surgery soon and do not have severe heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding PCSK9 inhibitor injections (to statin treatment) can slow or improve calcific aortic valve stenosis, a condition where the heart’s aortic valve becomes stiff and narrowed. It’s aimed at adults with mild-to-moderate disease or certain people with severe disease but no symptoms.
This Phase 2 trial tests pelacarsen (TQJ230), a medication that lowers a blood fat called lipoprotein(a), to see if it slows progression of calcific aortic valve stenosis. It may help people whose valve narrowing is starting to become more severe, especially when their lipoprotein(a) level is high.
This trial tests a drug called a PCSK9 inhibitor, which lowers cholesterol. It may slow down the buildup of calcium in the aortic valve, which can narrow the valve and make it harder for blood to flow. The drug is given as an injection, and you would receive it for 24 months.
This study tests whether a new injectable cholesterol-lowering drug (called a PCSK9 inhibitor) can help prevent further heart problems by making plaque in your arteries more stable and less likely to cause blocked vessels. It is for people who recently had a heart attack or unstable angina and already received a stent in the blocked artery.
This trial tests a new pill, ataciguat, to slow down the progression of moderate calcific aortic valve stenosis (a condition where your aortic valve stiffens). If you have moderate valve narrowing and meet the other criteria, participation could help find a way to delay needing surgery.
This trial tests whether adding a PCSK9 inhibitor to a statin is better than a statin alone for people with mild-to-moderate narrowing of the carotid artery (the main artery in the neck). It looks at how well these treatments slow plaque buildup and prevent strokes.
Hear when a new Aortic Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.